Table 1 Patient baseline characteristics and clinical outcomes

Pt (no.)	Prior Lines of Therapies (no.)	Prior SCT	Disease Status				Clinical Outcomes
			Disease Burden			CD33 Expression (%, by FCM)	Infusion Dose (10⁶/kg)	Safety			Efficacy
			BM blasts (%, by morphology)	BM blasts (%, by FCM)	EMD	CD33 Expression (%, by FCM)	Infusion Dose (10⁶/kg)	CRS	Neurotoxicity	DLT	Response at day 15	Response at day 30	Response within 3 months
1	2	NO	22.50	21.05	NO	99.79	0.5	1	0	0	PR	NR	MRD⁺ CRi
2	4	Allo-SCT	86.50	61.96	NO	99.93	0.5	4	1	1	MRD⁻ CRi	MRD⁻ CRi	MRD⁻ CRi
3	6	Allo-SCT	67.00	51.11	NO	98.80	0.5	2	0	0	MRD⁻ CRi	MRD⁻ CRi	MRD⁻ CRi
4	4	Allo-SCT	10.50	4.35	NO	99.30	0.5	2	1	0	MRD⁺ CRi	NR	NR

AML acute myeloid leukemia, BM bone marrow, CRi complete remission with incomplete hematologic recovery, CRS cytokine release syndrome, DLT dose-limiting toxicity, EMD extramedullary disease, MRD minimal residual disease, NR no response, PR partial remission, Pt patient, SCT stem cell transplantation.
Patient 1 received a second CAR T-cell infusion (3.76 × 10⁶/kg) on day 29 after the first CAR T-cell infusion. During the second infusion, the patient developed grade 2 CRS and was assessed as MRD− CRi 15 days after the second infusion, and the patient subsequently received SCT and has maintained disease-free.

Quick links

Search